Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies

被引：51

作者：

Janakiram, Murali ^{[1
,2
,3
]}

Pareek, Vipul ^{[1
,2
]}

Cheng, Haiying ^{[1
,2
]}

Narasimhulu, Deepa M. ^{[2
]}

Zang, Xingxing ^{[1
,2
,3
,4
]}

机构：

[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA

[2] Montefiore Med Ctr, Albert Einstein Coll Med, Oncol, Bronx, NY 10461 USA

[3] Montefiore Med Ctr, Albert Einstein Coll Med, Microbiol & Immunol, Bronx, NY 10461 USA

[4] Montefiore Med Ctr, Albert Einstein Coll Med, Urol, Bronx, NY 10461 USA

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 07期

关键词：

CTLA-4; Hodgkin lymphoma; immune checkpoint inhibitor; immunotherapy; leukemia; multiple myeloma; non-lymphoma; non-small-cell lung cancer; PD-1; PD-L1; squamous cell lung cancer; PD-1; BLOCKADE; PHASE-II; CELL; COMBINATION; NIVOLUMAB; ANTIBODY; SAFETY; INFILTRATION; PIDILIZUMAB; IPILIMUMAB;

D O I：

10.2217/imt-2016-0001

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/ PD-1 have had remarkable clinical success in several cancers and are less toxic than traditional chemotherapy. Even though only a small proportion of patients respond to checkpoint blockade, the duration of such responders due to immunological memory is remarkable and is longer than would be expected with any other agent in refractory disease. In this article, we review the therapeutic trials of blocking these pathways in human lung cancer and hematological malignancies.

引用

页码：809 / 819

页数：11

共 45 条

[11] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

[12] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[13] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[14] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[15] Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer [J].

Brambilla, Elisabeth ;

Le Teuff, Gwenael ;

Marguet, Sophie ;

Lantuejoul, Sylvie ;

Dunant, Ariane ;

Graziano, Stephen ;

Pirker, Robert ;

Douillard, Jean-Yves ;

Le Chevalier, Thierry ;

Filipits, Martin ;

Rosell, Rafael ;

Kratzke, Robert ;

Popper, Helmut ;

Soria, Jean-Charles ;

Shepherd, Frances A. ;

Seymour, Lesley ;

Tsao, Ming Sound .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (11) :1223-+

[16]

Bruce R, 2015, 57 AM SOC HEM SCI 8

[17] PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies [J].

Chen, Benjamin J. ;

Chapuy, Bjoern ;

Jing Ouyang ;

Sun, Heather H. ;

Roemer, Margaretha G. M. ;

Xu, Mina L. ;

Yu, Hongbo ;

Fletcher, Christopher D. M. ;

Freeman, Gordon J. ;

Shipp, Margaret A. ;

Rodig, Scott J. .

CLINICAL CANCER RESEARCH, 2013, 19 (13) :3462-3473

[18] Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia [J].

Christiansson, Lisa ;

Soderlund, Stina ;

Svensson, Emma ;

Mustjoki, Satu ;

Bengtsson, Mats ;

Simonsson, Bengt ;

Olsson-Stromberg, Ulla ;

Loskog, Angelica S. I. .

PLOS ONE, 2013, 8 (01)

[19] T-CELL ANTIGEN RECEPTOR GENES AND T-CELL RECOGNITION [J].

DAVIS, MM ;

BJORKMAN, PJ .

NATURE, 1988, 334 (6181) :395-402

[20] The three Es of cancer immunoediting [J].

Dunn, GP ;

Old, LJ ;

Schreiber, RD .

ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :329-360

← 1 2 3 4 5 →